pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2018-28-2-224-233pulmo-989Research ArticleОБЗОРЫREVIEWВозможности фиксированной комбинации индакатерола / гликопиррония при терапии хронической обструктивной болезни легких: обзор современных данныхEffects of fixed combination of indacaterol/glycopyrronium in chronic obstructive pulmonary disease: state-of-the art reviewАвдеевС. Н.AvdeevS. N.

д. м. н., член-корр. Российской академии наук, профессор, заведующий кафедрой пульмонологии Федерального государственного бюджетного образовательного учреждения высшего образования «Первый Московский государственный медицинский университет имени И.М.Сеченова» Министерства здравоохранения Российской Федерации, руководитель клинического отдела Федерального государственного бюджетного учреждения «Научно-исследовательский институт пульмонологии» Федерального медико-биологического агентства

Doctor of Medicine, Professor, Corresponding Member of Russian Academy of Sciences, Head of Department of Pulmonology, I.M.Sechenov First Moscow State Medical University, Healthcare Ministry of Russia (Sechenov University); Head of Clinical Division, Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia

serg_avdeev@list.ruТрушенкоН. В.TrushenkoN. V.

к. м. н., научный сотрудник научно-методического центра мониторинга и контроля болезней органов дыхания Федерального государственного бюджетного учреждения «Научно-исследовательский институт пульмонологии» Федерального медико-биологического агентства, ассистент кафедры пульмонологии Федерального государственного бюджетного образовательного учреждения высшего образования «Первый Московский государственный медицинский университет имени И.М.Сеченова» Министерства здравоохранения Российской Федерации

Candidate of Medicine, Researcher, Research Center for Monitoring and Control of Respiratory Diseases, Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia; Assistant Lecturer, Department of Pulmonology, I.M.Sechenov First Moscow State Medical University, Healthcare Ministry of Russia (Sechenov University)

trushenko.natalia@yandex.ruФедеральное государственное бюджетное образовательное учреждение высшего образования «Первый Московский государственный медицинский университет имени И.М.Сеченова» Министерства здравоохранения Российской Федерации; Федеральное государственное бюджетное учреждение «Научно-исследовательский институт пульмонологии» Федерального медико-биологического агентстваРоссияI.M.Sechenov First Moscow State Medical University, Healthcare Ministry of Russia (Sechenov University); Federal Pulmonology Research Institute, Federal Medical and Biological Agency of RussiaRussian Federation201830062018282224233Copyright © Авдеев С.Н., Трушенко Н.В., 20182018Авдеев С.Н., Трушенко Н.В.Avdeev S.N., Trushenko N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/989

Основными лекарственными средствами для лечения хронической обструктивной болезни легких (ХОБЛ) стабильного течения являются бронходилататоры длительного действия – длительно действующие β2-агонисты (ДДБА), длительно действующие антихолинергические препараты (ДДАХП) и их комбинации. Комбинированный препарат индакатерол / гликопирроний (ИНД / ГЛИ) − первая в мире фиксированная комбинация ДДБА / ДДАХП, для которой накоплена весомая доказательная база, подтверждающая ее эффективность при улучшении функциональных параметров, симптомов болезни, качества жизни пациентов и снижении частоты обострений ХОБЛ. Целью настоящего обзора результатов новейших исследований явилось подтверждение высокой клинической эффективности применения ИНД / ГЛИ, определяющей дальнейшие перспективы применения указанной комбинации у больных ХОБЛ.

Long-acting bronchodilators (long-acting β2-agonists (LABA), long-acting anticholinergics (LAMA) and their combinations) are the basic drugs for treatment of stable chronic obstructive pulmonary disease (COPD). Indacaterol/glycopyrronium (IND/GLY) is the first fixed LABA/LAMA combination acquired significant evidence of its efficacy for improvement lung function, symptoms, and quality of life, and decrease in the rate of acute exacerbations of COPD. The aim of this review was to reassess clinical efficacy of IND/GLY in treatment of COPD with regard to recent data and to outline the further role of this combination in therapy of COPD.

хроническая обструктивная болезнь легкихдвойная бронходилатациягиперинфляция легкихремоделированиесердечно-сосудистая системаиндакатерол / гликопирронийchronic obstructive pulmonary diseasedual bronchodilationlung hyperinflationremodelingcardiovascular systemindacaterol/glycopyrroniumReferencesRoche N. Stable COPD treatment: where are we? COPD. 2018, Apr. 2: 1–7. DOI: 10.1080/15412555.2018.1445214 [Epub ahead of print].Roche N. Stable COPD treatment: where are we? COPD. 2018, Apr. 2: 1–7. DOI: 10.1080/15412555.2018.1445214 [Epub ahead of print].GOLD 2018. Global Strategy for the Diagnosis, Management and Prevention of COPD. Updated 2018. Available at: http://www.goldcopd.org/ [Accessed 16 May, 2018].GOLD 2018. Global Strategy for the Diagnosis, Management and Prevention of COPD. Updated 2018. Available at: http://www.goldcopd.org/ [Accessed 16 May, 2018].Rossi A., Aisanov Z., Avdeev S. et al. Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD. Respir. Med. 2015; 109 (7): 785–802. DOI: 10.1016/j.rmed.2015.03.010.Rossi A., Aisanov Z., Avdeev S. et al. Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD. Respir. Med. 2015; 109 (7): 785–802. DOI: 10.1016/j.rmed.2015.03.010.Авдеев С.Н. Легочная гиперинфляция у больных хронической обструктивной болезнью легких. Пульмонология. 2006; (5): 82–96.Avdeev S.N. Lung hyperinflation in patients with chronic obstructive pulmonary disease. Pul’monologiya. 2006; (5): 82–96 (in Russian).Donohue J.F., Jones P.W., Bartels C. et al. Corrlations between FEV1 and patient-reported outcomes: A pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 2018; 49: 11–19. DOI: 10.1016/j.pupt.2017.12.005.Donohue J.F., Jones P.W., Bartels C. et al. Corrlations between FEV1 and patient-reported outcomes: A pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 2018; 49: 11–19. DOI: 10.1016/j.pupt.2017.12.005.Cazzola M., Calzetta L., Page C.P. et al. Translational study searching for synergy between glycopyrronium and indacaterol. COPD. 2014; 12 (2): 175–181. DOI: 10.3109/15412555.2014.922172.Cazzola M., Calzetta L., Page C.P. et al. Translational study searching for synergy between glycopyrronium and indacaterol. COPD. 2014; 12 (2): 175–181. DOI: 10.3109/15412555.2014.922172.Ficker J.H., Rabe K.F., Welte T. Role of dual bronchodilators in COPD: a review of the current evidence for indacaterol/glycopyrronium. Pulm. Pharmacol. Ther. 2017; 45: 19–33. DOI: 10.1016/j.pupt.2017.04.002.Ficker J.H., Rabe K.F., Welte T. Role of dual bronchodilators in COPD: a review of the current evidence for indacaterol/glycopyrronium. Pulm. Pharmacol. Ther. 2017; 45: 19–33. DOI: 10.1016/j.pupt.2017.04.002.Van der Molen T., Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim. Care. Respir. J. 2012; 21 (1): 101–108. DOI: 10.4104/pcrj.2011.00102.Van der Molen T., Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim. Care. Respir. J. 2012; 21 (1): 101–108. DOI: 10.4104/pcrj.2011.00102.Mahler D.A., Decramer M., D`Urzo A. et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study. Eur. Respir. J. 2014; 43 (6): 1599–1609. DOI: 10.1183/09031936.00124013.Mahler D.A., Decramer M., D`Urzo A. et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study. Eur. Respir. J. 2014; 43 (6): 1599–1609. DOI: 10.1183/09031936.00124013.Deas S.D., Huprikar N. Dual bronchodilatator therapy for chronic obstructive pulmonary disease: evidence for the efficacy and safety of fixed dose combination treatments in the setting of recent guideline updates. Curr. Opin. Pulm. Med. 2018; 24 (2): 130–137. DOI: 10.1097/MCP.0000000000000450.Deas S.D., Huprikar N. Dual bronchodilatator therapy for chronic obstructive pulmonary disease: evidence for the efficacy and safety of fixed dose combination treatments in the setting of recent guideline updates. Curr. Opin. Pulm. Med. 2018; 24 (2): 130–137. DOI: 10.1097/MCP.0000000000000450.Wedzicha J.A., Banerji D., Chapman K.R. et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N. Engl. J. Med. 2016; 374 (23): 2222–2234. DOI: 10.1056/NEJMoa1516385.Wedzicha J.A., Banerji D., Chapman K.R. et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N. Engl. J. Med. 2016; 374 (23): 2222–2234. DOI: 10.1056/NEJMoa1516385.Aisanov Z., Avdeev S., Arkhipov V. et al. Russian guidelines for the management of COPD: algorithm of pharmacologic treatment. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; (13): 183–187. DOI: 10.2147/COPD.S153770.Aisanov Z., Avdeev S., Arkhipov V. et al. Russian guidelines for the management of COPD: algorithm of pharmacologic treatment. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; (13): 183–187. DOI: 10.2147/COPD.S153770.Айсанов З.Р., Авдеев С.Н., Архипов В.В. и др. Национальные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких: алгоритм принятия клинических решений. Пульмонология. 2017; 27 (1): 13–20. DOI: 10.18093/0869-0189-2017-27-1-13-20.Aisanov Z.R., Avdeev S.N., Arkhipov V.V. et al. National clinical guidelines on diagnosis and treatment of chronic obstructive pulmonary disease: a clinical decision-making algorithm. Pul’monologiya. 2017; 27 (1): 13–20. DOI: 10.18093/0869-0189-2017-27-1-13-20 (in Russian).Авдеев С.Н., Трушенко Н.В. Двойная бронходилатация новая парадигма длительной терапии хронической обструктивной болезни легких. Практическая пульмонология. 2015; (3): 24–32.Avdeev S.N., Trushenko N.V. Dual bronchodilation: a novel paradigm of continued therapy of chronic obstructive pulmonary disease. Prakticheskaya pul’monologiya. 2015; (3): 24–32 (in Russian).Авдеев С.Н. Значение фиксированных комбинаций длительно действующих антихолинергических препаратов и длительно действующих b2-агонистов в терапии хронической обструктивной болезни легких. Пульмонология. 2015; 25 (1): 93–100. DOI: 10.18093/0869-0189-2015-25-1-93-100.Avdeev S.N. A role of fixed combinations of long-acting anticholinergics and long-acting β2-agonists in treatment of chronic obstructive pulmonary disease. Pul’monologiya. 2015; 25 (1): 93–100. DOI: 10.18093/0869-0189-2015-25-1-93-100 (in Russian).Cazzola M., Rogliani P. Comparative effectiveness of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease. J. Comp. Eff. Res. 2017; 6 (7): 627–636. DOI: 10.2217/cer-2017-0037.Cazzola M., Rogliani P. Comparative effectiveness of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease. J. Comp. Eff. Res. 2017; 6 (7): 627–636. DOI: 10.2217/cer-2017-0037.Bateman E.D., Ferguson G.T., Barnes N. et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur. Respir. J. 2013; 42 (6): 1484–1494. DOI: 10.1183/09031936.00200212.Bateman E.D., Ferguson G.T., Barnes N. et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur. Respir. J. 2013; 42 (6): 1484–1494. DOI: 10.1183/09031936.00200212.Mahler D.A., Kerwin E., Ayers T. et al. FLIGHT1 and FLIGHT2: efficacy and safety of QVA149 (Indacaterol/Glycopyrrolate) versus its monocomponents and placebo in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2015; 192 (9): 1068–1079. DOI: 10.1164/rccm.201505-1048OC.Mahler D.A., Kerwin E., Ayers T. et al. FLIGHT1 and FLIGHT2: efficacy and safety of QVA149 (Indacaterol/Glycopyrrolate) versus its monocomponents and placebo in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2015; 192 (9): 1068–1079. DOI: 10.1164/rccm.201505-1048OC.Calzetta L., Rogliani P., Matera M.G., Cazzola M. A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment stable COPD. Chest. 2016; 149 (5): 1181–1196. DOI: 10.1016/j.chest.2016.02.646.Calzetta L., Rogliani P., Matera M.G., Cazzola M. A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment stable COPD. Chest. 2016; 149 (5): 1181–1196. DOI: 10.1016/j.chest.2016.02.646.Vogelmeier C.F., Gaga M., Aalamian-Mattheis M. et al. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respir. Res. 2017; 18 (1): 140. DOI: 10.1186/s12931-017-0622-x.Vogelmeier C.F., Gaga M., Aalamian-Mattheis M. et al. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respir. Res. 2017; 18 (1): 140. DOI: 10.1186/s12931-017-0622-x.Zhong N., Wang C., Zhou N. et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Int. J. Сhron. Obstruct. Pulmon. Dis. 2015; 5 (10): 1015–1026. DOI: 10.2147/COPD.S84436.Zhong N., Wang C., Zhou N. et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Int. J. Сhron. Obstruct. Pulmon. Dis. 2015; 5 (10): 1015–1026. DOI: 10.2147/COPD.S84436.Vogelmeier C.F., Bateman E.D., Pallante J. et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir. Med. 2013; 1 (1): 51–60. DOI: 10.1016/S2213-2600(12)70052-8.Vogelmeier C.F., Bateman E.D., Pallante J. et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir. Med. 2013; 1 (1): 51–60. DOI: 10.1016/S2213-2600(12)70052-8.Beeh K.M., Korn S., Beier J. et al. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respir. Med. 2014; 108 (4): 584–592. DOI: 10.1016/j.rmed.2014.01.006.Beeh K.M., Korn S., Beier J. et al. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respir. Med. 2014; 108 (4): 584–592. DOI: 10.1016/j.rmed.2014.01.006.Martinez F.J., Foster G., Curtis J.L. et al. Predictors of mortality in patients with emphysema and severe airflow obstruction. Am. J. Respir. Crit. Care Med. 2006; 173 (12): 1326–1334. DOI: 10.1164/rccm.200510-1677OC.Martinez F.J., Foster G., Curtis J.L. et al. Predictors of mortality in patients with emphysema and severe airflow obstruction. Am. J. Respir. Crit. Care Med. 2006; 173 (12): 1326–1334. DOI: 10.1164/rccm.200510-1677OC.Barr R.G., Bluemke D.A., Ahmed F.S. et al. Percent emphysema, airflow obstruction and impaired left ventricular filling. N. Engl. J. Med. 2010; 362 (3): 217–227. DOI: 10.1056/NEJMoa0808836.Barr R.G., Bluemke D.A., Ahmed F.S. et al. Percent emphysema, airflow obstruction and impaired left ventricular filling. N. Engl. J. Med. 2010; 362 (3): 217–227. DOI: 10.1056/NEJMoa0808836.Kawut S.M., Poor H.D., Parikh M.A. et al. Cor pulmonale parvus in chronic obstructive pulmonary disease and emphysema: the MESA COPD study. J. Am. Coll. Cardiol. 2014; 64 (19): 2000–2009. DOI: 10.1016/j.jacc.2014.07.991.Kawut S.M., Poor H.D., Parikh M.A. et al. Cor pulmonale parvus in chronic obstructive pulmonary disease and emphysema: the MESA COPD study. J. Am. Coll. Cardiol. 2014; 64 (19): 2000–2009. DOI: 10.1016/j.jacc.2014.07.991.Watz H., Waschki B., Meyer T. et al. Decreasing cardiac chamber sizesand associated heart dysfunction in COPD: role of hyperinflation. Chest. 2010; 138 (1): 32–38. DOI: 10.1378/chest.09-2810.Watz H., Waschki B., Meyer T. et al. Decreasing cardiac chamber sizesand associated heart dysfunction in COPD: role of hyperinflation. Chest. 2010; 138 (1): 32–38. DOI: 10.1378/chest.09-2810.Smith B.M., Prince M.R., Hoffman E.A. et al. Impaired left ventricular filling in COPD and emphysema: is it the heart or the lungs? The Multi-Ethnic Study of Atherosclerosis COPD Study. Chest. 2013; 144 (4): 1143–1151. DOI: 10.1378/chest.13-0183.Smith B.M., Prince M.R., Hoffman E.A. et al. Impaired left ventricular filling in COPD and emphysema: is it the heart or the lungs? The Multi-Ethnic Study of Atherosclerosis COPD Study. Chest. 2013; 144 (4): 1143–1151. DOI: 10.1378/chest.13-0183.Hohfeld J.M., Vogel-Claussen J., Biller H. et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Lancet Respir. Med. 2018; 6 (5): 368–378. DOI: 10.1016/S2213-2600(18)30054-7.Hohfeld J.M., Vogel-Claussen J., Biller H. et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Lancet Respir. Med. 2018; 6 (5): 368–378. DOI: 10.1016/S2213-2600(18)30054-7.Ferguson G., Barnes N., Mehta R. et al. Cardio- and cerebro-vascular safety profile of QVA149 in patients with COPD: a pooled analysis. Eur. Respir. J. 2013; 42 (Suppl. 57): P4139.Ferguson G., Barnes N., Mehta R. et al. Cardio- and cerebro-vascular safety profile of QVA149 in patients with COPD: a pooled analysis. Eur. Respir. J. 2013; 42 (Suppl. 57): P4139.Авдеев С.Н. Новая фиксированная комбинация длительнодействующих антихолинергика гликопиррония бромида и β2-агониста индакатерола: перспективы терапии ХОБЛ. Медицинский совет 2016; (15): 11–16. DOI: 10.21518/2079-701X-2016-15-11-16.Avdeev S.N. A novel fixed combination of long-acting anticholinergic glycopyrronium bromide and long-acting β2-agonist indacaterol: perspectives of therapy for COPD. Meditsinskiy sovet. 2016; (15): 11–16. DOI: 10.21518/2079-701X-2016-15-11-16 (in Russian).Wedzicha J.A., Dahl R., Buhl R. et al. Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients. Respir. Med. 2014; 108 (10): 1498–1507. DOI: 10.1016/j.rmed.2014.07.011.Wedzicha J.A., Dahl R., Buhl R. et al. Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients. Respir. Med. 2014; 108 (10): 1498–1507. DOI: 10.1016/j.rmed.2014.07.011.Авдеев С.Н. Стратегии профилактики обострений хронической обструктивной болезни легких. Доктор.ру. 2017; 10 (139): 40–48.Avdeev S.N. Preventive strategies for acute exacerbation of chronic obstructive pulmonary disease. Doktor.ru. 2017; 10 (139): 40–48 (in Russian).Anzueto A.R., Vogelmeier C.F., Kostikas K. et al. The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; (12): 1325–1337. DOI: 10.2147/COPD.S133307.Anzueto A.R., Vogelmeier C.F., Kostikas K. et al. The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; (12): 1325–1337. DOI: 10.2147/COPD.S133307.Beeh K.M., Burgel P.R., Franssen F.M.E. et al. How do dual long-acting bronchodilators prevent exacerbations of chronic obstructive pulmonary disease? Am. J. Respir. Crit. Care Med. 2017; 196 (2): 139–149. DOI: 10.1164/rccm.201609-1794CI.Beeh K.M., Burgel P.R., Franssen F.M.E. et al. How do dual long-acting bronchodilators prevent exacerbations of chronic obstructive pulmonary disease? Am. J. Respir. Crit. Care Med. 2017; 196 (2): 139–149. DOI: 10.1164/rccm.201609-1794CI.Bhatt S.P., Soler X., Wang X. et al. Association between functional small airway disease and FEV1 decline in COPD. Am. J. Respir. Crit. Care Med. 2016; 194 (2): 178–84. DOI: 10.1164/rccm.201511-2219OC.Bhatt S.P., Soler X., Wang X. et al. Association between functional small airway disease and FEV1 decline in COPD. Am. J. Respir. Crit. Care Med. 2016; 194 (2): 178–84. DOI: 10.1164/rccm.201511-2219OC.Gohy S.T., Detry B.R., Lecocq M. et al. Polymeric immunoglobulin receptor down-regulation in chronic obstructive pulmonary disease. Persistence in the cultured epithelium and role of transforming growth factor-β. Am. J. Respir. Crit. Care Med. 2014; 190 (5): 509–521. DOI: 10.1164/rccm.201311-1971OC.Gohy S.T., Detry B.R., Lecocq M. et al. Polymeric immunoglobulin receptor down-regulation in chronic obstructive pulmonary disease. Persistence in the cultured epithelium and role of transforming growth factor-β. Am. J. Respir. Crit. Care Med. 2014; 190 (5): 509–521. DOI: 10.1164/rccm.201311-1971OC.Kistemaker L.E., Oenema T.A., Meurs H., Gosens R. Regulation of airway inflammation and remodeling by muscarinic receptors: perspectives on anticholinergic therapy in asthma and COPD. Life Sci. 2012; 91 (21-22): 1126–1133. DOI: 10.1016/j.lfs.2012.02.021.Kistemaker L.E., Oenema T.A., Meurs H., Gosens R. Regulation of airway inflammation and remodeling by muscarinic receptors: perspectives on anticholinergic therapy in asthma and COPD. Life Sci. 2012; 91 (21-22): 1126–1133. DOI: 10.1016/j.lfs.2012.02.021.Haag S., Matthiesen S., Juergens U.R., Racke K. Muscarinic receptors mediate stimulation of collagen synthesis in human lung fibroblasts. Eur. Respir. J. 2008; 32 (3): 555–562. DOI: 10.1183/09031936.00129307.Haag S., Matthiesen S., Juergens U.R., Racke K. Muscarinic receptors mediate stimulation of collagen synthesis in human lung fibroblasts. Eur. Respir. J. 2008; 32 (3): 555–562. DOI: 10.1183/09031936.00129307.Wessler I., Kirkpatrick C.J. Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans. Br. J. Pharmacol. 2008; 154 (8): 1558–1571. DOI: 10.1038/bjp.2008.185.Wessler I., Kirkpatrick C.J. Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans. Br. J. Pharmacol. 2008; 154 (8): 1558–1571. DOI: 10.1038/bjp.2008.185.Namba Y., Togo S., Tulafu M. et al. Combination of glycopyrronium and indacaterol inhibits carbachol-induced ERK5 signal in fibrotic processes. Respir. Res. 2017; 18 (1): 46. DOI: 10.1186/s12931-017-0529-6.Namba Y., Togo S., Tulafu M. et al. Combination of glycopyrronium and indacaterol inhibits carbachol-induced ERK5 signal in fibrotic processes. Respir. Res. 2017; 18 (1): 46. DOI: 10.1186/s12931-017-0529-6.Profita M., Bonanno A., Siena L. et al. Smoke, choline acetyltransferase, muscarinic receptors and fibroblast proliferation in chronic obstructive pulmonary disease. J. Pharmacol. Exp. Ther. 2009; 329 (2): 753–63. DOI: 10.1124/jpet.108.145888.Profita M., Bonanno A., Siena L. et al. Smoke, choline acetyltransferase, muscarinic receptors and fibroblast proliferation in chronic obstructive pulmonary disease. J. Pharmacol. Exp. Ther. 2009; 329 (2): 753–63. DOI: 10.1124/jpet.108.145888.

The authors declare that there are no conflicts of interest present.